MedTrace Logo

Anti TNF α Improves Endothelial Dysfunction in IBD Patients

NCT01881464 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2014-05-16

No results posted yet for this study

Summary

Study hypothesis - this study will assess the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.

Conditions

Interventions

DEVICE

Endopath from Itamar medical - FDA approved device.

endothelial function assessment by Endopath device

DRUG

Anti TNF Alfa.

This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.

Sponsors & Collaborators

  • Carmel Medical Center

    lead OTHER

Principal Investigators

  • Zittan Eran · CARMEL MEDICAL CENTER - HAIFA -ISRAEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-06-30
Completion
2018-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01881464 on ClinicalTrials.gov